On June, 11 Analysts See $-0.45 EPS for Rhythm Pharmaceuticals, Inc. (RYTM)

May 17, 2018 - By Lisa Delgado

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM)’s earnings report is expected by WallStreet on June, 11, according to RTT. Wall Street now sees 9.76 % negative EPS growth despite Rhythm Pharmaceuticals, Inc. previous quarter’s EPS of $-0.41. RYTM hit $30.78 during the last trading session after $0.94 change.Rhythm Pharmaceuticals, Inc. has 145,865 shares volume, 44.87% up from normal. RYTM is and has moved 0.00% since May 17, 2017. The stock underperformed the S&P 500 by 11.55%.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States.The firm is valued at $847.00 million. The Company’s lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alstr??m syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders.Last it reported negative earnings. The firm was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.

More recent Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) news were posted by Nasdaq.com, Nasdaq.com and Globenewswire.com. The first one has “Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference” as a title and was posted on May 09, 2018. The next is “Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of …” on May 09, 2018. And last was posted on May 14, 2018, called “Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results”.

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.